vs
Side-by-side financial comparison of Bristol Myers Squibb (BMY) and Johnson & Johnson (JNJ), based on the latest 10-Q / 10-K filings. Click either name above to swap in a different company.
Johnson & Johnson is the larger business by last-quarter revenue ($24.6B vs $12.5B, roughly 2.0× Bristol Myers Squibb). Johnson & Johnson runs the higher net margin — 8.7% vs 20.8%, a 12.1% gap on every dollar of revenue. On growth, Johnson & Johnson posted the faster year-over-year revenue change (9.1% vs 1.3%). Johnson & Johnson produced more free cash flow last quarter ($5.5B vs $1.6B). Over the past eight quarters, Johnson & Johnson's revenue compounded faster (7.2% CAGR vs 2.6%).
Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban (Eliquis) for people with atrial fibrillation ; nivolumab (Opdivo), used to treat certain types of cancer ; lenalidomide (Revlimid), used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes ; abatacept (Orencia), used to treat autoimmune diseases such as rheumatoid art...
Johnson & Johnson (J&J) is an American multinational pharmaceutical, biotechnology, and medical technologies corporation headquartered in New Brunswick, New Jersey, and publicly traded on the New York Stock Exchange. Its common stock is a component of the Dow Jones Industrial Average, and the company is ranked No. 48 on the 2025 Fortune 500 list of the largest United States corporations. In 2025, the company was ranked 42th in the Forbes Global 2000.
BMY vs JNJ — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $12.5B | $24.6B |
| Net Profit | $1.1B | $5.1B |
| Gross Margin | 67.2% | 67.6% |
| Operating Margin | 11.8% | 20.2% |
| Net Margin | 8.7% | 20.8% |
| Revenue YoY | 1.3% | 9.1% |
| Net Profit YoY | 1409.7% | 49.1% |
| EPS (diluted) | $0.54 | $2.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align — see 8-quarter trend below.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history — bar widths are scaled to the larger of the two companies so you can eyeball the size gap and growth trajectory without doing math. Quarters aligned by calendar period (report date) so offset fiscal years line up.
| Q4 25 | $12.5B | $24.6B | ||
| Q3 25 | $12.2B | $24.0B | ||
| Q2 25 | $12.3B | $23.7B | ||
| Q1 25 | $11.2B | $21.9B | ||
| Q4 24 | $12.3B | $22.5B | ||
| Q3 24 | $11.9B | $22.5B | ||
| Q2 24 | $12.2B | $22.4B | ||
| Q1 24 | $11.9B | $21.4B |
| Q4 25 | $1.1B | $5.1B | ||
| Q3 25 | $2.2B | $5.2B | ||
| Q2 25 | $1.3B | $5.5B | ||
| Q1 25 | $2.5B | $11.0B | ||
| Q4 24 | $72.0M | $3.4B | ||
| Q3 24 | $1.2B | $2.7B | ||
| Q2 24 | $1.7B | $4.7B | ||
| Q1 24 | $-11.9B | $3.3B |
| Q4 25 | 67.2% | 67.6% | ||
| Q3 25 | 71.9% | 69.6% | ||
| Q2 25 | 72.5% | 67.9% | ||
| Q1 25 | 72.9% | 66.4% | ||
| Q4 24 | 61.0% | 68.3% | ||
| Q3 24 | 75.1% | 69.0% | ||
| Q2 24 | 73.2% | 69.4% | ||
| Q1 24 | 75.3% | 69.6% |
| Q4 25 | 11.8% | 20.2% | ||
| Q3 25 | 25.5% | 31.2% | ||
| Q2 25 | 14.5% | 27.3% | ||
| Q1 25 | 26.5% | 62.3% | ||
| Q4 24 | 1.4% | 17.3% | ||
| Q3 24 | 14.1% | 14.9% | ||
| Q2 24 | 10.5% | 25.6% | ||
| Q1 24 | -97.1% | 17.4% |
| Q4 25 | 8.7% | 20.8% | ||
| Q3 25 | 18.0% | 21.5% | ||
| Q2 25 | 10.7% | 23.3% | ||
| Q1 25 | 21.9% | 50.2% | ||
| Q4 24 | 0.6% | 15.2% | ||
| Q3 24 | 10.2% | 12.0% | ||
| Q2 24 | 13.8% | 20.9% | ||
| Q1 24 | -100.4% | 15.2% |
| Q4 25 | $0.54 | $2.08 | ||
| Q3 25 | $1.08 | $2.12 | ||
| Q2 25 | $0.64 | $2.29 | ||
| Q1 25 | $1.20 | $4.54 | ||
| Q4 24 | $0.05 | $1.41 | ||
| Q3 24 | $0.60 | $1.11 | ||
| Q2 24 | $0.83 | $1.93 | ||
| Q1 24 | $-5.89 | $1.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest filing — the kind of financial-strength check premium terminals charge for.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $10.2B | $20.1B |
| Total DebtLower is stronger | $44.8B | $41.4B |
| Stockholders' EquityBook value | $18.5B | $81.5B |
| Total Assets | $90.0B | $199.2B |
| Debt / EquityLower = less leverage | 2.43× | 0.51× |
8-quarter trend — quarters aligned by calendar period so offset fiscal years match up.
| Q4 25 | $10.2B | $20.1B | ||
| Q3 25 | $15.7B | $18.6B | ||
| Q2 25 | $12.6B | $18.9B | ||
| Q1 25 | $10.9B | $38.8B | ||
| Q4 24 | $10.3B | $24.5B | ||
| Q3 24 | $7.9B | $20.3B | ||
| Q2 24 | $6.3B | $25.5B | ||
| Q1 24 | $9.3B | $26.2B |
| Q4 25 | $44.8B | $41.4B | ||
| Q3 25 | $48.7B | — | ||
| Q2 25 | $48.9B | — | ||
| Q1 25 | $49.5B | — | ||
| Q4 24 | $49.4B | $32.4B | ||
| Q3 24 | $49.5B | — | ||
| Q2 24 | $52.0B | — | ||
| Q1 24 | $52.4B | — |
| Q4 25 | $18.5B | $81.5B | ||
| Q3 25 | $18.6B | $79.3B | ||
| Q2 25 | $17.4B | $78.5B | ||
| Q1 25 | $17.4B | $78.1B | ||
| Q4 24 | $16.3B | $71.5B | ||
| Q3 24 | $17.1B | $70.2B | ||
| Q2 24 | $17.0B | $71.5B | ||
| Q1 24 | $16.5B | $70.0B |
| Q4 25 | $90.0B | $199.2B | ||
| Q3 25 | $96.9B | $192.8B | ||
| Q2 25 | $94.7B | $193.4B | ||
| Q1 25 | $92.4B | $193.7B | ||
| Q4 24 | $92.6B | $180.1B | ||
| Q3 24 | $93.7B | $178.3B | ||
| Q2 24 | $94.6B | $181.1B | ||
| Q1 24 | $99.0B | $172.0B |
| Q4 25 | 2.43× | 0.51× | ||
| Q3 25 | 2.63× | — | ||
| Q2 25 | 2.81× | — | ||
| Q1 25 | 2.85× | — | ||
| Q4 24 | 3.03× | 0.45× | ||
| Q3 24 | 2.89× | — | ||
| Q2 24 | 3.05× | — | ||
| Q1 24 | 3.18× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Net income can be massaged; cash flow is harder to fake.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.0B | $7.3B |
| Free Cash FlowOCF − Capex | $1.6B | $5.5B |
| FCF MarginFCF / Revenue | 12.8% | 22.3% |
| Capex IntensityCapex / Revenue; lower = less reinvestment burden | 3.0% | 7.5% |
| Cash ConversionOCF / Net Profit; >1× = earnings back up with cash | 1.82× | 1.43× |
| TTM Free Cash FlowTrailing 4 quarters | $12.8B | $19.7B |
8-quarter trend — quarters aligned by calendar period so offset fiscal years match up.
| Q4 25 | $2.0B | $7.3B | ||
| Q3 25 | $6.3B | $9.2B | ||
| Q2 25 | $3.9B | $3.9B | ||
| Q1 25 | $2.0B | $4.2B | ||
| Q4 24 | $4.4B | $7.0B | ||
| Q3 24 | $5.6B | $8.0B | ||
| Q2 24 | $2.3B | $5.6B | ||
| Q1 24 | $2.8B | $3.7B |
| Q4 25 | $1.6B | $5.5B | ||
| Q3 25 | $6.0B | $8.0B | ||
| Q2 25 | $3.6B | $2.8B | ||
| Q1 25 | $1.7B | $3.4B | ||
| Q4 24 | $4.1B | $5.4B | ||
| Q3 24 | $5.3B | $7.0B | ||
| Q2 24 | $2.1B | $4.7B | ||
| Q1 24 | $2.5B | $2.9B |
| Q4 25 | 12.8% | 22.3% | ||
| Q3 25 | 49.0% | 33.4% | ||
| Q2 25 | 29.0% | 11.9% | ||
| Q1 25 | 15.1% | 15.4% | ||
| Q4 24 | 32.9% | 23.8% | ||
| Q3 24 | 44.3% | 31.0% | ||
| Q2 24 | 16.9% | 20.7% | ||
| Q1 24 | 21.5% | 13.3% |
| Q4 25 | 3.0% | 7.5% | ||
| Q3 25 | 2.6% | 4.8% | ||
| Q2 25 | 2.9% | 4.4% | ||
| Q1 25 | 2.3% | 3.6% | ||
| Q4 24 | 3.1% | 7.2% | ||
| Q3 24 | 2.7% | 4.6% | ||
| Q2 24 | 2.1% | 4.3% | ||
| Q1 24 | 2.4% | 3.8% |
| Q4 25 | 1.82× | 1.43× | ||
| Q3 25 | 2.87× | 1.78× | ||
| Q2 25 | 2.99× | 0.70× | ||
| Q1 25 | 0.80× | 0.38× | ||
| Q4 24 | 61.65× | 2.04× | ||
| Q3 24 | 4.62× | 2.97× | ||
| Q2 24 | 1.38× | 1.20× | ||
| Q1 24 | — | 1.12× |
Financial Flow Comparison
Sankey diagram of revenue → gross profit → operating profit → net profit for each company. Charts shown full-width and stacked so both segment hierarchies are readable side-by-side on desktop and mobile.
Revenue Breakdown by Segment
BMY
| Net Product Sales | $12.1B | 97% |
| Zeposia | $159.0M | 1% |
| Opdivo Ovantig | $132.0M | 1% |
| Abecma | $100.0M | 1% |
| Sotyktu | $86.0M | 1% |
JNJ
| Other | $14.2B | 58% |
| Immunology | $2.5B | 10% |
| Orthopaedics | $1.5B | 6% |
| Neuroscience | $1.4B | 6% |
| Cardiovascular | $1.4B | 6% |
| Surgery | $1.1B | 4% |
| Pulmonary Hypertension | $865.0M | 4% |
| Cardiovascular Metabolism Other | $794.0M | 3% |
| Vision | $531.0M | 2% |
| Infectious Diseases | $303.0M | 1% |
